Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Did you mean sodium phosphate dibasic anhydrous and sodium phosphate monobasic monohydrate?
Displaying drugs 13951 - 13975 of 14731 in total

Becotatug

Becotatug is under investigation in clinical trial NCT06380348 (JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations).
Investigational

Lilotomab

Lilotomab is under investigation in clinical trial NCT01796171 (A Phase 1/2 Study of Betalutin for Treatment of Relapsed Non-hodgkin Lymphoma).
Investigational

Izokibep

Izokibep is under investigation in clinical trial NCT05623345 (Psoriatic Arthritis Study of Izokibep).
Investigational

Shigella sonnei strain 53G

Investigational

Gotistobart

Gotistobart is under investigation in clinical trial NCT05671510 (ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors).
Investigational

Simoladagene autotemcel

Investigational

Sotevtamab

Sotevtamab is under investigation in clinical trial NCT06225843 (Sotevtamab (AB-16B5) Combined With FOLFOX as Neoadjuvant Treatment Prior to Resection of Colorectal Cancer Liver Metastasis).
Investigational

Seproxetine

Seproxetine is also known as (S)-norfluoxetine. It is a selective serotonin reuptake inhibitor (SSRI). It is an active metabolite of fluoxetine. Seproxetine was being investigated by Eli Lilly as an antidepressant but development was never completed and the drug was never marketed.
Investigational
Matched Description: … Seproxetine was being investigated by Eli Lilly as an antidepressant but development was never completed and …

Giredestrant

Giredestrant is under investigation in clinical trial NCT06065748 (A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With Er-positive, Her2-negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (Pionera Breast Cancer)).
Investigational
Matched Description: … Giredestrant is under investigation in clinical trial NCT06065748 (A Study to Evaluate Efficacy and Safety …

[4,6-O-(1-CARBOXYETHYLIDENE)-BETA-D-MANNOSE]

Experimental

(2R)-2-PHENYL-N-PYRIDIN-4-YLBUTANAMIDE

Experimental

[2-(3-DIBENZOFURAN-4-YL-PHENYL)-1-HYDROXY-1-PHOSPHONO-ETHYL]-PHOSPHONIC ACID

Experimental

5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine

Experimental

N~4~-methyl-N~4~-(3-methyl-1H-indazol-6-yl)-N~2~-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine

Experimental

4-(1H-IMIDAZOL-1-YL)PHENOL

Experimental

(5S)-5-(3-AMINOPROPYL)-3-(2,5-DIFLUOROPHENYL)-N-ETHYL-5-PHENYL-4,5-DIHYDRO-1H-PYRAZOLE-1-CARBOXAMIDE

Experimental

N-acetylsulfanilyl chloride

ASC has been investigated for the screening of Patients Undergoing Screening or Surveillance Colonoscopy.
Investigational

3-hydroxyisoxazole-4-carboxylic acid

Experimental

Carpropamide

Experimental

4-Sulfonamide-[1-(4-Aminobutane)]Benzamide

Experimental

1-cyclobutyl-3-(3,4-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine

Experimental

(1R,2R)-N-(2-Aminoethyl)-2-{[(4-methoxyphenyl)sulfonyl]methyl}cyclohexanecarboxamide

Experimental

Cambendazole

Experimental
Vet approved

CG-200745

Cg200745 has been used in trials studying the treatment of Solid Tumour.
Investigational

iCo-007

iCo-007 (formerly known as ISIS 13650) is a second generation antisense compound being developed by iCo for the treatment of various eye diseases caused by the formation of new blood vessels (angiogenesis) such as age-related macular degeneration (AMD) and diabetic retinopathy(DR).
Investigational
Matched Description: … by the formation of new blood vessels (angiogenesis) such as age-related macular degeneration (AMD) and …
Displaying drugs 13951 - 13975 of 14731 in total